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upon which life-long interventions including lifestyle and phar-
macotherapy are then based. Advances in genomics may help 
identify individuals with genetic vulnerability to ASCVD and 
the recognition of the importance of duration of exposure to 
risk factors such as low-density lipoprotein (LDL)-cholesterol 
(LDL-C), blood pressure(1) or number of cigarettes (pack-years) 
are helping to reshape the paradigm of risk assessment with 
greater precision (Figure 1). These are likely to move the 
approach of health systems from ones treating disease to ones 
which aim to preserve health (Figure 2). Central to this aim is 
the move from short-term risk assessment to lifetime risk and 
earlier implementation of preventive strategies.(2) In this article, 
we highlight some of the key scientific observations in the field 
of prevention in 2019 from risk assessment, and epidemiology 
with an additional focus on lipids, diabetes, and hypertension.
A recurring observation is that conventional risk assessment is 
imprecise and the addition of information from imaging con-
sistently helps to correctly reclassify individuals. As a result, the 
use of imaging and in particular coronary artery calcification 
(CAC) has been shown to be superior to other modalities and 
is therefore encouraged among those at intermediate risk and 
the presence of subclinical atherosclerotic disease supports 
earlier and more targeted CV prevention strategies in the 
new ESC/EAS and ESC/EASD 2019 guidelines.(3,4) Moreover, 
absence of CAC may also reclassify risk down and that should 
be considered in a shared decision environment. Imaging 
modalities which lend themselves to machine learning such as 
evaluation of perivascular fat in cardiac computer tomography 
may well allow imaging to be scaled up, and become repro-
ducible and cost-effective as part of the risk assessment tool.(5)
While imaging is clearly important its use is likely to be useful 
after decades of exposure to risk factors and still provides 
assessment for short- to intermediate-term risk. Recently, a 
lifetime-perspective CardioVascular Disease (LIFE-CVD) model 
for the estimation of treatment-effects of cholesterol-lowering, 
blood pressure lowering, antithrombotic therapy, and smoking 
cessation in apparently healthy people has been developed. 
This freely accessible online calculator (www.U-Prevent.com) 
estimates risk and treatment effects in terms of improved 10-
year risk, lifetime risk, and life-expectancy free of CVD and is 
designed to facilitate doctor–patient communication.(6)  Large 





Advances in genomics, understanding of the effects of cumu-
lative exposure and various environmental risk factors have 
moved us closer to better models of care focused at early risk 
assessment and treatment to prevent cardiovascular (CV) 
disease. We review relevant contributions in 2019 to the field 
of CV disease prevention, with a focus on epidemiology, lipids, 
diabetes, and hypertension.
EVOLVING CONCEPTS IN PREVENTION
Current concepts for risk assessment for the primary preven-
tion of atherosclerotic cardiovascular disease (ASCVD) are 
based on assessments of multiple risk factors and global risk 
when one high-risk condition such as diabetes, genetic dyslip-
idaemia, or hypertension is absent. These are usually measured 
at a specific time point and predict short-term risk (10 years) 
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detection of AF by a smartwatch sensing technology reduces 
the risk of CV events. However, there are also concerns that 
widespread use of such approaches, particularly in the low risk, 
younger populations using such devices, may lead to unneces-
sary medical consultations,(9) making an assessment of studies 
such as HEARTLIVE in appropriate populations important.
BEHAVIOUR AND ENVIRONMENTAL FACTORS
Genetics
Considerable amounts of data have emerged from UK Biobank. 
However, data are needed on non-European populations as 
∼10 000 of the 500 000 cohort are from south Asian or 
Afrocarribean ancestry.
Behaviour may, in part, have a genetic basis. In a Mendelian 
randomisation analysis from UK Biobank, genetic variants 
known to affect educational attainment were associated with 
health-conscious lifestyle later in life, and which in turn may 
subsequently affect the risk of coronary artery disease.(10)
a time horizon of 50 years will never occur. However, the 
importance of early and sustained reduction in risk factors, 
notably LDL-C and blood pressure, were highlighted in anal-
yses from UK Biobank where a 1 mmol/L lower LDL-C and 
a 10mmHg lower blood pressure were associated with an 
80% lower risk of CV disease.(1)  Put more simply, small dif-
ferences maintained over a long time produce cumulative 
benefits.(1)  Moreover, higher levels of CV risk factors are 
associated with worse brain health across grey and white matter 
macrostructure and microstructure in relatively healthy middle 
and older age individuals, suggesting that common risk factor 
modification could improve a current health burden in late-life, 
namely dementia.(7)
Digital health technology is rapidly advancing and sensors may 
allow earlier detection of conditions associated with increased 
CV risk, such as atrial fibrillation (AF).(8) While compelling evi-
dence for their effectiveness is largely lacking, large scale studies 
have been initiated. The HEARTLIVE study enrolling ∼150 000 
participants (>65 years of age) is assessing whether earlier 
FIGURE 1: Life time trajectory of gene-environment interactions towards cardiovascular disease and death.
The figure illustrates the impact of life time exposure to both genetic and life style/environmental causal risk factors that determine the 
development and clinical course of cardiovascular disease. A better understanding of opportunities for a more effective preservation of health is 






















Data are conflicting with different recommendations regarding 
red meat consumption. Observational studies suggested 
potential carcinogenic effects of processed meat.(11)  Four 
systematic reviews on the health effects of red meat and one 
systematic review on individual health-related values and pre-
ferences regarding meat consumption have been published,(12) 
where the magnitudes of any effect were small. Additionally, 
these studies report only very low to low certainty for any 
association of unprocessed or processed red meat intake 
with CV mortality, diabetes, or cancer. The authors conclude 
that individuals continue their current consumption of both 
processed and unprocessed meat, albeit with a weak 
recommendation because of the low certainty around the 
evidence.(12) Of note, a recent randomised dietary study sug-
gests that chronic dietary red meat consumption increases 
systemic levels of trimethylamine N-oxide (TMAO), a micro-
biome-dependent metabolite, that has been associated with 
increased CV risk,(13) but larger studies are needed.
Carbohydrates
Conflicting data on the role of carbohydrates for ASCVD risk 
have led to different recommendations. For example, the large 
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Prospective Urban Rural Epidemiology (PURE) study reported 
that high carbohydrate intake was associated with higher risk 
of total mortality.(14)  In contrast, a recent analysis of the 
National Health and Nutrition Examination Survey (NHANES; 
1999 - 2010) suggests exactly the opposite, with low carbo-
hydrate diets associated with excess overall and cause-specific 
mortality.(15)  Nutritional epidemiology carries the risk of con-
founding by social and economic factors. The underlying causal 
association (if any) of behaviour, such as “skipping breakfast”, 
with ASCVD may be unrelated to discussions about the 
benefit of fat vs. carbohydrates,(16)  therefore, the evidence to 
support population-level interventions such as increasing the 
price of high sugar snacks appears incomplete, especially since 
this would differentially affect low-income individuals.(17) More 
recently, the totality of the literature of this topic was sum-
marised by a U-shaped relationship between carbohydrate 
intake and mortality.(18) The authors conclude that “taking all 
the studies into account, the message of moderation is per-
haps the most convincing one of all – diets that focus too 
heavily on a single macronutrient, whether extreme protein, 
carbohydrate, or fat intake, may adversely impact health. The 
best advice seems to be to select whole foods from a variety 
of sources and avoid dietary extremism. For now, for carbo-
hydrates, everything in moderation seems to carry the day”.(18)
FIGURE 2: Missed opportunities in reducing the health care burden, improving quality of life, delaying death – exemplar 
for common conditions.
The figure shows potential opportunities for more effective prevention strategies during the course of subclinical and clinical cardiovascular 
disease development; e.g. atherosclerotic cardiovascular disease develops and progresses over several decades providing numerous opportunities 
for prevention before clinical manifestations of the disease.
Innovative ways of identifying those on an accelerated course
Genomics, imaging, digital health records and AI to help 
predict and manage risk
Offering medications that change the trajectory/life course
by magnitude of effect and duration of treatment- 
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Innovative treatments used but in too few and 
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The notion that the effect of any diet on body weight is in turn 
proportional to risk of ASCVD may be over-simplistic.(19)  In 
the Women’s Health Initiative, during a median of 17.9 years 
of follow-up, whole body fat mass was not associated with 
incident ASCVD among normal weight post-menopausal 
women. Interestingly, the distribution of fat was, with higher 
trunk fat associated with higher risk of ASCVD, while higher 
leg fat predicted lower risk.(20) These data suggest an adverse 
fat distribution and risk can be characterised by increased 
(unfavourable) abdominal/visceral (trunk) and decreased 
(beneficial) lower body (leg) fat that is independent of body 
fat mass. Future research should address potential mechanisms 
for the development of adverse fat distribution and how it may 
be linked to atherosclerosis.(19,20)
Sleep duration
Data from the Prospective Urban Rural Epidemiology (PURE) 
study on 116 632 with follow-up of 7.8 years that show that 
estimated total sleep duration of 6 - 8 hours per day is 
associated with the lowest risk of deaths and major CV 
events.(21)  Interestingly, a neuro-immune axis that links sleep 
to haematopoiesis and atherosclerosis has been identif ied 
and provides a mechanistic rationale for disturbed sleep and 
increased CV risk.(22)
Smoking
Recent data from the Framingham Heart Study provide 
quantitative information on the positive health effects of 
smoking cessation based on >25 years of follow-up showing 
that quitting within 5 years was associated with 39% lower 
risk of incident CVD compared with current smokers. Also, 
among heavy smokers, smoking cessation was associated with 
lower risk of CVD relative to current smokers.(23) The health 
effects of e-cigarettes (so-called “vaping”) are still uncertain, 
and recent case reports suggest potential emerging clinical 
syndromes that are not yet completely understood.(24)
Exercise
Increased physical activity, at any intensity and less time spent 
sedentary, is associated with substantially reduced risk for pre-
mature mortality.(25)  However, translation into patient care 
and individualised training recommendations remain a chal-
lenge. A randomised controlled trial showed that endurance 
and interval training but not resistance training, induced effects 
on circulating blood cells that are important for cellular 
senescence and regenerative capacity, showing that different 
training modalities exert differential cellular and vascular effects 
contributing to vascular health.(26)
Noise, pollution, and workplace
There is increasing awareness of associations between our 
environment and health. For instance, ambient air pollution has 
been linked to an excess annual mortality rate of 659 000 in 
the European Union (EU-28), with the majority attributable 
to CV causes.(27)  Estimates put attributable per capita annual 
mortality rate in Europe at 133/100 000, but considerable 
uncertainty around this estimate remains.(27)  In this regard, a 
nationwide cohort study from Switzerland modelled long-term 
exposure to noise levels as well as environmental pollutants 
for each address of four million adults.(28)  The data suggest 
that road traff ic, aircraft, and railway noise are each asso-
ciated with excess mortality from myocardial infarction (MI), 
independent of air pollution. The authors suggest that air 
pollution studies not adequately adjusting for noise exposure 
may overestimate the attributable burden of risk from air 
pollution.(28,29)
Finally, large cohort studies from Sweden and Denmark reveal 
that 9% reported being bullied at work and 13% recorded 
exposure to workplace violence during the preceding year. 
After adjustment, being bullied at work was associated with 
59% increased risk of ASCVD. The population attributable risk 
was dose-dependent and overall 5.0% for workplace bullying 
and 3.1% for workplace violence.(30)
DYSLIPIDAEMIA AND LIPIDS
Several clinical trial programmes have studied novel treatment 
options for modification of lipoprotein-related risk of ASCVD 
that are described below, e.g. new options for lowering LDL-
cholesterol and triglyceride-rich lipoproteins. These novel 
therapeutic approaches will allow a more effective and tar-
geted strategy for management of lipoprotein-related risk in 
the future (Figure 3). 
Low-density lipoprotein-cholesterol
ATP citrate lyase is an enzyme in the cholesterol-biosynthesis 
pathway upstream of 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase (HMGCR), the target of statins. Genetic variants that 
mimic the effect of ATP citrate lyase inhibitors and statins 
appeared to lower plasma LDL-cholesterol levels by the same 
mechanism of action and were associated with similar effects 
on the risk of CV disease per unit decrease in the LDL-
cholesterol level.(31)  Bempedoic acid, an inhibitor of ATP 
citrate lyase, reduced levels of LDL cholesterol by 16.5% when 
added to maximally tolerated statin therapy,(32)  and a clinical 
outcomes study is ongoing.
Recent data from trials of ezetemibe and PCSK9 monoclonal 
antibodies demonstrating consistent evidence of benefit with 
the achievement of lower risk among patients with lower 
LDL-C levels have now been incorporated into the new ESC/
EAS treatment guidelines in 2019, with 55mg/dL the new goal 
for very high-risk patients.(3)
24
Triglyceride-rich lipoproteins
In a genetic study, it was observed that triglyceride-lowering 
lipoprotein lipase variants and LDL-C-lowering LDL-receptor 
variants were associated with a similar lower risk of coronary 
heart disease per unit difference in ApoB, suggesting that the 
clinical benefit of lipid lowering per se  is proportional to the 
absolute change in ApoB.(33)  Icosapent ethyl, a highly purified 
eicosapentaenoic acid ethyl ester, lowered triglyceride levels, 
and reduced ischaemic events by 26% in the recent REDUCE-
IT trial in patients with elevated triglyceride levels compared 
to mineral oil.(34)  The magnitude of benefit was greater than 
that expected by ApoB changes alone, suggesting mechanisms 
beyond ApoB lowering.(34,35)
Lipoprotein (a)
A recent analysis of >65 000 subjects suggested that lipopro-
tein(a) levels >93mg/dL (199nmol/L; 96th - 100th percentiles) 
vs. <10mg/dL (18nmol/L; 1st - 50th percentiles) was associated 
with a 50% excess risk for CV mortality and of 20% for all-
cause mortality.(36)  The authors hypothesise that elevated 
lipoprotein(a), (through corresponding low LPA KIV-2 number 
of repeats) rather than through Lp(a) cholesterol content, were 
the drivers of this excess risk.(36)
HYPERTENSION
Epidemiology
Hypertension is a very important risk factor for CV disease 
and five decades of trials have demonstrated the benefits of 
pharmacotherapy in reducing CV morbidity and mortality. 
However, contemporary data reinforce the need for improve-
ment in hypertension healthcare globally. In 12 high-income 
countries, data from more than half a million participants 
indicated greatly improved hypertension awareness, treat-
ment, and control since the 1980s, but substantial varia-
tions in hypertension prevalence and treatment across 
countries.(37)  Control rates have plateaued in recent decades 
with rates of treatment coverage ∼80% and control ∼70% in 
best performing countries. Conversely, in 44 low-income and 
middle-income countries, only 40% of those with hypertension 
were diagnosed, with 30% receiving antihypertensive medi-
cation, and 10% controlled with disparity across countries and 
sub-Saharan Africa performing the worst.(38)
Blood pressure measurement
A study from 1.3 million North American patients has shown 
that both systolic blood pressure (SBP) and diastolic blood 
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FIGURE 3: Developments in lipid-targeted therapies.
Genetic studies have provided important insights into causal genes and related lipoproteins for development and progression of atherosclerotic 
vascular disease. Whereas initial management steps will remain life style optimisation and statin therapy, a more focused treatment depending on 
the lipoprotein profile is currently being developed in addition to these treatment options, focusing on low-density lipoprotein-cholesterol-
related risk, lipoprotein(a), and triglyceride-rich lipoproteins. 
*no outcomes data available. AB = antibody, ASO = anti sense oligonuceotide, EPA = eicosapentanoeic acid, FDC = fixed dose combination, 


























pressure (DBP) independently predicted MI, ischaemic/haem-
orrhagic stroke with a greater effect of systolic hyperten-
sion.(39)  Importantly, the relationship between SBP, DBP, and 
events is independent of treatment threshold (≥140/90mmHg 
vs. ≥130/80mmHg), supporting the more proactive manage-
ment of hypertension in high-risk individuals in recent guide-
lines.(40–42) The IDACO investigators observed in a study of 
11 135 adults, that higher 24 hours and night-time SBP were 
signif icantly associated with greater risks of death and CV 
events even after adjusting for other office-based or ambulatory 
BP measurements,(43)  reinforcing recent guidelines recom-




While there have been no developments in novel therapies 
for hypertension, an increasing focus is the use of multi-
drug combinations, even as an initial step in treatment. Most 
recently, the WHO added fixed dose combination anti-
hypertensive medications to the Essential Medicines List, with 
the aim of addressing inequalities in treatment and control in 
low to middle income countries (LMIC).(44) This approach has 
already demonstrated cost-effectiveness in patients in Sri Lanka 
with mild-moderate hypertension treated with a triple pill 
strategy vs. usual care, providing the first economic evaluation 
of a triple-pill approach.(45)
Evidence is accumulating to support nocturnal dosing of anti-
hypertensive medication, with the Hygia Chronotherapy trial, 
the first ABPM-based outcome study providing evidence that 
bed-time dosing of ≥1 antihypertensive drug, vs. morning, 
results in better ambulatory BP control, lower sleep-time BP 
and improved nocturnal dipper status.(46)  Despite modest 
differences in BP,(46) there was a disproportionate reduction in 
CVD morbidity and mortality with bedtime dosing with no 
safety signal noted. Whether this is real requires independent 
confirmation.
Device therapy
Endovascular renal denervation (RDN) aims to achieve durable 
hypertension control through interruption of renal sympathetic 
nervous system signalling. The open label, single arm Global 
Symplicity Registry have reported signif icant and sustained 
reductions in ambulatory and office BP (−16.5 ± 28.6mmHg 
and −8.0 ± 20.0mmHg, respectively) 3 years post-radiofre-
quency ablation with no safety signal and preserved renal 
function in 1 742 patients.(47)  Furthermore, the RADIANCE-
HTN SOLO investigators have now shown that the effects 
of endovascular ultrasound RDN in patients with mild-
moderate hypertension are preserved at 6 months, with less 
medication burden compared with sham control.(13,48) It is 
unclear which, if any, of the technologies to achieve RDN is 
superior: radiofrequency (RF) vs. ultrasound (US) vs. alcohol 
chemical ablation. However, the RADIOSOUND-HTN investi-
gators have shown in patients with resistant hypertension, 
endovascular US-based RDN achieved similar BP reduction to 
RF ablation of the main arteries, accessories, and side 
branches, but was superior to RF ablation of the main renal 
arteries only.(49)  Furthermore, while the search for marker of 
procedural success and predictors of response to RDN is 
ongoing, the SPYRAL HTN-OFF MED investigators have 
demonstrated that RF RDN in patients with mild-moderate 
hypertension resulted in signif icant heart rate reduction 
compared to sham and that hypertensive patients with higher 
heart rates may be more likely to respond.(48)
DIABETES
The prevalence of diabetes is increasing, with >425 million 
already affected globally, potentially growing to 629 million by 
2045.(4) As diabetes doubles the risk of CVD, the increase in 
prevalence will increase the population attributable risk 
disproportionately in low-middle income countries where the 
disposable income and economic growth coupled with 
sedentary lifestyle are seeing the greatest rise in diabetes 
prevalence. Novel therapeutic options now offer a chance to 
move away from prior glucose-centric approaches in diabetes 
care to those aimed at preventing cardio-renal complications, 
as evidenced by the 2019 ESC guidelines on diabetes, pre-
diabetes, and CV diseases developed in collaboration with the 
European Association for the Study of Diabetes (EASD).(4) 
A key premise of these is the classification of absolute CV 
risk as the first step, into  Very high,  High, and Moderate 
risk.  Based on the results of recent trials, using both GLP1-
RAs and SGLT2 inhibitors, in the 2019 guidelines, these drug 
classes are recommended as first-line therapy in patients with 
T2DM and established ASCVD or at high/very high CV risk, 
such as those with target-organ damage or multiple risk 
factors instead of metformin.(4)  Among those already on 
metformin, GLP1-RAs and SGLT2 inhibitors should be added 
for CV risk reduction with the aim of moving away from a 
HbA1c-centric approach to one which prevents CV disease.
Notable contributions from several large trials in 2019 include 
the REWIND trial(50) assessing the effect of once weekly sub-
cutaneous dulaglutide vs. placebo on three-point major 
adverse cardiac events (MACE) in 9 901 patients with T2DM, 
who had either a previous CV event or multiple risk factors. 
Over 5.4 years of follow-up, the primary composite outcome 
occurred in 12.0% of participants in the dulaglutide group and 
in 13.4% in the placebo group, reflecting a significant 12% 
relative risk reduction. The DECLARE-TIMI 58 trial(51)  investi-
gated the effect of dapagliflozin vs. placebo in 17 160 patients 
with DM and established CVD or multiple risk factors. After 
26
4.2 years of follow-up, the pre-specified criterion for non-
inferiority for the composite MACE was met by dapagliflozin 
compared with placebo. In 2 primary eff icacy analyses, 
dapagliflozin did not significantly reduce 3P-MACE, but resulted 
in a lower rate of the combined endpoint of CV death or HF 
hospitalisation by 17% (4.9% vs. 5.8% absolute difference). The 
benefit on heart failure was similar in patients with CVD as 
well as those with multiple risk factors only. A recent meta-
analysis of the SGLT2i trials suggested consistent benefits on 
reducing the composite of HF hospitalisation or CV death, as 
well as on the progression of kidney disease, regardless of 
presence of established CVD, while the reduction in MACE 
was only apparent in ASCVD patients.(52) Previous CVOTs 
with SGLT2 inhibitors demonstrated renal benefit as a 
secondary endpoint, but the CREDENCE trial(53) was the first 
dedicated study assessing renal preservation with SGLT2i in 
chronic kidney disease and diabetes (estimated glomerular 
filtration rate 30 - <90mL/min/1.73 m2). Individuals randomised 
to canagliflozin had a relative reduction in the primary renal 
outcome of 30% compared to placebo. In addition, canagliflozin 
significantly reduced the prespecified secondary CV outcomes 
of 3P-MACE by 20% and hospitalisation for heart failure by 
29% compared with placebo. More recently, there is now 
compelling evidence that SGLT2 inhibition reduces heart failure 
in populations with heart failure and reduced ejection fraction 
equally among those with or without diabetes in the DAPA 
CHF trial.(54)
INFLAMMATION AND THROMBOSIS
The CANTOS trial provided the first evidence that targeting 
inflammation reduced CV outcomes in those with established 
disease. Ultimately cost, questions regarding duration of therapy 
and efficacy vs. safety “trade off ” with increased infections have 
not seen the development of IL-1beta antagonism. Targeting 
inflammation indirectly, with low-cost safe alternatives has been 
sought with methotrexate showing no benefit. Among patients 
with a recent MI, low-dose colchicine reduced a broad com-
posite CV endpoint including revascularisation by 23% (1.6% 
absolute benefit) in the COLCOT trial.(55) Colchicine use was 
associated with an absolute excess of 0.8% in diarrhoea (NS) 
and 0.5% in pneumonia (P = 0.03).
Finally, aspirin clearly has net benefit (more CV events voided 
than significant bleeds caused) in the setting of established CV 
disease or secondary prevention. However, the observation 
that in over 100 000 patients in primary prevention trials of 
aspirin demonstrated an excess of about 2.5 excess major 
bleeds for each non-fatal MI averted and no mortality benefit 
over 5 years.(56) As such, aspirin is not routinely recommended 
in the ESC guidelines in the setting of primary prevention.(57)
SUMMARY AND CONCLUSIONS
The present article summarises important advances in the 
field of CV prevention in 2019. We have highlighted the 
increasing role of considering lifetime CV risk for maintaining 
CV health, as well as the need for risk assessment in patients 
with established ASCVD or diabetes, for which novel and 
more targeted preventive therapies have been developed and 
proven effective.
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